Immunotherapies such as checkpoint-blocking antibodies and adoptive cell transfer are
emerging as treatments for a growing number of cancers. Despite clinical activity of …

AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family
(RTKs), and its abnormal expression has been linked to clinicopathological features and …

Background. In the face of poor prognosis and immunotherapy failure of gastric cancer (GC),
this project tried to find new potential biomarkers for predicting prognosis and precision …

Transcriptomic signatures designed to predict melanoma patient responses to PD-1
blockade have been reported but rarely validated. We now show that intra-patient …

Novel treatment approaches are needed to overcome innate and acquired mechanisms of
resistance to current anticancer therapies in cancer cells and the tumour immune …

Triple negative breast cancer (TNBC) represents the 15–20% of all breast cancers (BC) and
is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a …

Mouse syngeneic tumor models are widely used tools to demonstrate activity of novel anti-
cancer immunotherapies. Despite their widespread use, a comprehensive view of their …

Intratumor heterogeneity is a key factor contributing to therapeutic failure and, hence, cancer
lethality. Heterogeneous tumors show partial therapy responses, allowing for the emergence …

The TAM receptor family of TYRO3, AXL and MERTK regulates tissue and immune
homeostasis. Aberrant TAM receptor signalling has been linked to a range of diseases …

Receptor tyrosine kinases have been shown to dysregulate a number of pathways
associated with tumor development, progression, and metastasis. Axl is a receptor tyrosine …